• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Tricuspid repair in patients with mitral regurgitation offers clinical benefits

byDavid XiangandHarsh Shah
January 31, 2022
in Cardiology, Chronic Disease, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with severe degenerative mitral regurgitation who received mitral-valve surgery, those who also received tricuspid regurgitation surgery had less frequent progression to severe tricuspid regurgitation.

2. Incidence of pacemaker implantation was higher in patients who received concomitant tricuspid repair along with mitral-valve surgery.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Tricuspid regurgitation is commonly seen in patients undergoing mitral valve surgery for severe degenerative mitral regurgitation. However, there is wide practice variability in the management of less-than-severe tricuspid regurgitation at the time of left-sided heart surgery, and there is a gap in knowledge as to understanding the benefits and risks of tricuspid-valve repair at the time of mitral-valve surgery for patients with degenerative mitral regurgitation and less severe tricuspid regurgitation. This study found that patients who received tricuspid-valve repair along with mitral-valve surgery had significantly slower progression of tricuspid regurgitation and a significantly lower incidence of reoperation for tricuspid regurgitation, though the rate of pacemaker implantation was higher in patients who also received tricuspid-valve surgery. This study was limited by a non-diverse patient population and a limited primary endpoint of 24 months, which may not fully capture the clinical progression of tricuspid regurgitation. Nevertheless, these study’s findings are significant, as they demonstrate that performing both tricuspid and mitral valve surgery simultaneously for patients with severe mitral regurgitation and moderate tricuspid regurgitation resulted in less frequent progression of tricuspid regurgitation.

Click to read the study in NEJM

Relevant Reading: The Price of Freedom from Tricuspid Regurgitation

In-Depth [randomized control trial]: This randomized control trial included 401 patients at 39 clinical centers in the United States, Canada, and Germany: 203 who received mitral-valve surgery alone and 198 who received mitral-valve surgery and tricuspid annuloplasty (TA). Patients who had degenerative mitral regurgitation with either moderate tricuspid regurgitation or less-than-moderate regurgitation with annular dilatation of 40 mm or more were included in the study. Patients who had evidence of secondary mitral regurgitation, primary tricuspid-valve disease, and suboptimal volume management were excluded from the study. The primary outcome measured was at 2 years and consisted of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation from baseline, or death. Outcomes in the primary analysis were assessed in the intention-to-treat population using a log-binomial regression model of treatment failure. In patients who received both mitral and tricuspid valve surgery, they had significantly fewer primary end-point events compared to those who only received mitral-valve surgery (3.9% vs 10.2%) (95% confidence interval [CI], 0.16 to 0.86). Furthermore, at 2 years, the progression of tricuspid regurgitation was significantly lower in the mitral and tricuspid valve surgery group compared to the mitral valve surgery group (0.6% vs. 6.1%; 95% CI, 0.01 to 0.69). However, the incidence of pacemaker implantation was significantly higher in the mitral and tricuspid valve surgery group as compared to the mitral valve surgery group (14.1% vs. 2.5%; 95% CI, 2.27 to 14.60). Overall, this study demonstrated that in patients with severe mitral regurgitation undergoing mitral-valve surgery, also performing tricuspid valve surgery if they had tricuspid regurgitation led to a significantly slower progression of the tricuspid disease and need for reoperation, though the long-term clinical benefit can be determined only with longer follow-up.

RELATED REPORTS

MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial

The COAPT: Transcatheter mitral valve repair lowers mortality in patients with heart failure and mitral regurgitation

2 Minute Medicine Rewind December 1 – December 7, 2014

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: mitral regurgitationmitral valvemitral-valve surgerytricuspid annuloplastytricuspid regurgitationtricuspid valve
Previous Post

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

Next Post

Australian RSV epidemic seasonality – but not severity – altered by COVID-19

RelatedReports

MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial
Cardiology

MitraClip does not significantly improve outcomes in secondary mitral regurgitation: the MITRA-FR trial

December 14, 2018
Patient Basics: Heart Murmur
Cardiology

The COAPT: Transcatheter mitral valve repair lowers mortality in patients with heart failure and mitral regurgitation

December 13, 2018
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

2 Minute Medicine Rewind December 1 – December 7, 2014

December 9, 2014
Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)
Cardiology

2 Minute Medicine Rewind November 18-24, 2013

November 25, 2013
Next Post
Parents with poor sleep quality report sleep problems in kids

Australian RSV epidemic seasonality – but not severity – altered by COVID-19

Low evidence for glycerin use in preterm infants

Extreme prematurity associated with increased prevalence of visual and ocular deficits in young adults

Large proportion of late preterm infants and older admitted to the NICU

Preeclampsia and perinatal complications associated with increased risk neurodevelopmental and psychiatric diagnoses

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options